| Mosunmola Adebowale Ademosu, MD | |
|
355 New Shackle Island Rd, Hendersonville, TN 37075 | |
| (615) 338-1000 | |
| Not Available |
| Full Name | Mosunmola Adebowale Ademosu |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 17 Years |
| Location | 355 New Shackle Island Rd, Hendersonville, Tennessee |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003234006 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 56387 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Jackson-madison County General Hospital | Jackson, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| West Tennessee Healthcare Hospitalists Inc | 1951735521 | 79 |
News Archive
It is unclear how a consent form approved last week by the Oklahoma State Board of Health for the state's law requiring parental consent for minors seeking abortion will be enforced and which agency will enforce it, the Tulsa World reports.
The first clinical trial to investigate whether treatment with a statin drug can reduce the increased cardiovascular disease risk in people infected with HIV has begun enrolling patients. Based at Massachusetts General Hospital, the six-year, $40 million REPRIEVE (Randomized Study to Prevent Vascular Events in HIV) trial will be conducted at around 100 sites in the U.S., Canada, Puerto Rico and Thailand with funding from the National Heart, Lung, and Blood Institute in collaboration with the AIDS Clinical Trials Group and support from the National Institutes of Allergy and Infectious Diseases.
Ipsen today announced that the scientific journal Pediatrics published the detailed results of the phase III randomized study showing both the efficacy and the safety of Dysport in the treatment of dynamic equinus foot deformity, a condition associated with cerebral palsy in children.
Adolescent girls participating in high-impact physical activity, specifically basketball, running and gymnastics/cheerleading, appear to be at increased risk for developing stress fractures, according to a report posted online today that will appear in the August print issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.
The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
› Verified 7 days ago
| Entity Name | Southeastern Physician Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083835441 PECOS PAC ID: 0042307852 Enrollment ID: O20071025000571 |
News Archive
It is unclear how a consent form approved last week by the Oklahoma State Board of Health for the state's law requiring parental consent for minors seeking abortion will be enforced and which agency will enforce it, the Tulsa World reports.
The first clinical trial to investigate whether treatment with a statin drug can reduce the increased cardiovascular disease risk in people infected with HIV has begun enrolling patients. Based at Massachusetts General Hospital, the six-year, $40 million REPRIEVE (Randomized Study to Prevent Vascular Events in HIV) trial will be conducted at around 100 sites in the U.S., Canada, Puerto Rico and Thailand with funding from the National Heart, Lung, and Blood Institute in collaboration with the AIDS Clinical Trials Group and support from the National Institutes of Allergy and Infectious Diseases.
Ipsen today announced that the scientific journal Pediatrics published the detailed results of the phase III randomized study showing both the efficacy and the safety of Dysport in the treatment of dynamic equinus foot deformity, a condition associated with cerebral palsy in children.
Adolescent girls participating in high-impact physical activity, specifically basketball, running and gymnastics/cheerleading, appear to be at increased risk for developing stress fractures, according to a report posted online today that will appear in the August print issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.
The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
› Verified 7 days ago
| Entity Name | Cogent Healthcare Of Tennessee, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952654246 PECOS PAC ID: 8628221165 Enrollment ID: O20130110000564 |
News Archive
It is unclear how a consent form approved last week by the Oklahoma State Board of Health for the state's law requiring parental consent for minors seeking abortion will be enforced and which agency will enforce it, the Tulsa World reports.
The first clinical trial to investigate whether treatment with a statin drug can reduce the increased cardiovascular disease risk in people infected with HIV has begun enrolling patients. Based at Massachusetts General Hospital, the six-year, $40 million REPRIEVE (Randomized Study to Prevent Vascular Events in HIV) trial will be conducted at around 100 sites in the U.S., Canada, Puerto Rico and Thailand with funding from the National Heart, Lung, and Blood Institute in collaboration with the AIDS Clinical Trials Group and support from the National Institutes of Allergy and Infectious Diseases.
Ipsen today announced that the scientific journal Pediatrics published the detailed results of the phase III randomized study showing both the efficacy and the safety of Dysport in the treatment of dynamic equinus foot deformity, a condition associated with cerebral palsy in children.
Adolescent girls participating in high-impact physical activity, specifically basketball, running and gymnastics/cheerleading, appear to be at increased risk for developing stress fractures, according to a report posted online today that will appear in the August print issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.
The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
› Verified 7 days ago
| Entity Name | App Of Tennessee Hm, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396160768 PECOS PAC ID: 5395960694 Enrollment ID: O20140630001088 |
News Archive
It is unclear how a consent form approved last week by the Oklahoma State Board of Health for the state's law requiring parental consent for minors seeking abortion will be enforced and which agency will enforce it, the Tulsa World reports.
The first clinical trial to investigate whether treatment with a statin drug can reduce the increased cardiovascular disease risk in people infected with HIV has begun enrolling patients. Based at Massachusetts General Hospital, the six-year, $40 million REPRIEVE (Randomized Study to Prevent Vascular Events in HIV) trial will be conducted at around 100 sites in the U.S., Canada, Puerto Rico and Thailand with funding from the National Heart, Lung, and Blood Institute in collaboration with the AIDS Clinical Trials Group and support from the National Institutes of Allergy and Infectious Diseases.
Ipsen today announced that the scientific journal Pediatrics published the detailed results of the phase III randomized study showing both the efficacy and the safety of Dysport in the treatment of dynamic equinus foot deformity, a condition associated with cerebral palsy in children.
Adolescent girls participating in high-impact physical activity, specifically basketball, running and gymnastics/cheerleading, appear to be at increased risk for developing stress fractures, according to a report posted online today that will appear in the August print issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.
The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
› Verified 7 days ago
| Entity Name | Hospital Medicine Services Of Tennessee Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528433802 PECOS PAC ID: 9234432881 Enrollment ID: O20160114002673 |
News Archive
It is unclear how a consent form approved last week by the Oklahoma State Board of Health for the state's law requiring parental consent for minors seeking abortion will be enforced and which agency will enforce it, the Tulsa World reports.
The first clinical trial to investigate whether treatment with a statin drug can reduce the increased cardiovascular disease risk in people infected with HIV has begun enrolling patients. Based at Massachusetts General Hospital, the six-year, $40 million REPRIEVE (Randomized Study to Prevent Vascular Events in HIV) trial will be conducted at around 100 sites in the U.S., Canada, Puerto Rico and Thailand with funding from the National Heart, Lung, and Blood Institute in collaboration with the AIDS Clinical Trials Group and support from the National Institutes of Allergy and Infectious Diseases.
Ipsen today announced that the scientific journal Pediatrics published the detailed results of the phase III randomized study showing both the efficacy and the safety of Dysport in the treatment of dynamic equinus foot deformity, a condition associated with cerebral palsy in children.
Adolescent girls participating in high-impact physical activity, specifically basketball, running and gymnastics/cheerleading, appear to be at increased risk for developing stress fractures, according to a report posted online today that will appear in the August print issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.
The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
› Verified 7 days ago
| Entity Name | West Tennessee Healthcare Hospitalists Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720635188 PECOS PAC ID: 1951735521 Enrollment ID: O20200107003009 |
News Archive
It is unclear how a consent form approved last week by the Oklahoma State Board of Health for the state's law requiring parental consent for minors seeking abortion will be enforced and which agency will enforce it, the Tulsa World reports.
The first clinical trial to investigate whether treatment with a statin drug can reduce the increased cardiovascular disease risk in people infected with HIV has begun enrolling patients. Based at Massachusetts General Hospital, the six-year, $40 million REPRIEVE (Randomized Study to Prevent Vascular Events in HIV) trial will be conducted at around 100 sites in the U.S., Canada, Puerto Rico and Thailand with funding from the National Heart, Lung, and Blood Institute in collaboration with the AIDS Clinical Trials Group and support from the National Institutes of Allergy and Infectious Diseases.
Ipsen today announced that the scientific journal Pediatrics published the detailed results of the phase III randomized study showing both the efficacy and the safety of Dysport in the treatment of dynamic equinus foot deformity, a condition associated with cerebral palsy in children.
Adolescent girls participating in high-impact physical activity, specifically basketball, running and gymnastics/cheerleading, appear to be at increased risk for developing stress fractures, according to a report posted online today that will appear in the August print issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.
The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
› Verified 7 days ago
| Entity Name | Hospitalist Medicine Physicians Of Tennessee-tcg, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740768233 PECOS PAC ID: 3072911452 Enrollment ID: O20211015001276 |
News Archive
It is unclear how a consent form approved last week by the Oklahoma State Board of Health for the state's law requiring parental consent for minors seeking abortion will be enforced and which agency will enforce it, the Tulsa World reports.
The first clinical trial to investigate whether treatment with a statin drug can reduce the increased cardiovascular disease risk in people infected with HIV has begun enrolling patients. Based at Massachusetts General Hospital, the six-year, $40 million REPRIEVE (Randomized Study to Prevent Vascular Events in HIV) trial will be conducted at around 100 sites in the U.S., Canada, Puerto Rico and Thailand with funding from the National Heart, Lung, and Blood Institute in collaboration with the AIDS Clinical Trials Group and support from the National Institutes of Allergy and Infectious Diseases.
Ipsen today announced that the scientific journal Pediatrics published the detailed results of the phase III randomized study showing both the efficacy and the safety of Dysport in the treatment of dynamic equinus foot deformity, a condition associated with cerebral palsy in children.
Adolescent girls participating in high-impact physical activity, specifically basketball, running and gymnastics/cheerleading, appear to be at increased risk for developing stress fractures, according to a report posted online today that will appear in the August print issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.
The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
› Verified 7 days ago
| Entity Name | Hospitalist Medicine Physicians Of Texas-tcg Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902384464 PECOS PAC ID: 3678825312 Enrollment ID: O20220127001398 |
News Archive
It is unclear how a consent form approved last week by the Oklahoma State Board of Health for the state's law requiring parental consent for minors seeking abortion will be enforced and which agency will enforce it, the Tulsa World reports.
The first clinical trial to investigate whether treatment with a statin drug can reduce the increased cardiovascular disease risk in people infected with HIV has begun enrolling patients. Based at Massachusetts General Hospital, the six-year, $40 million REPRIEVE (Randomized Study to Prevent Vascular Events in HIV) trial will be conducted at around 100 sites in the U.S., Canada, Puerto Rico and Thailand with funding from the National Heart, Lung, and Blood Institute in collaboration with the AIDS Clinical Trials Group and support from the National Institutes of Allergy and Infectious Diseases.
Ipsen today announced that the scientific journal Pediatrics published the detailed results of the phase III randomized study showing both the efficacy and the safety of Dysport in the treatment of dynamic equinus foot deformity, a condition associated with cerebral palsy in children.
Adolescent girls participating in high-impact physical activity, specifically basketball, running and gymnastics/cheerleading, appear to be at increased risk for developing stress fractures, according to a report posted online today that will appear in the August print issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.
The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mosunmola Adebowale Ademosu, MD 355 New Shackle Island Rd, Hendersonville, TN 37075-2479 Ph: (615) 338-1000 | Mosunmola Adebowale Ademosu, MD 355 New Shackle Island Rd, Hendersonville, TN 37075 Ph: (615) 338-1000 |
News Archive
It is unclear how a consent form approved last week by the Oklahoma State Board of Health for the state's law requiring parental consent for minors seeking abortion will be enforced and which agency will enforce it, the Tulsa World reports.
The first clinical trial to investigate whether treatment with a statin drug can reduce the increased cardiovascular disease risk in people infected with HIV has begun enrolling patients. Based at Massachusetts General Hospital, the six-year, $40 million REPRIEVE (Randomized Study to Prevent Vascular Events in HIV) trial will be conducted at around 100 sites in the U.S., Canada, Puerto Rico and Thailand with funding from the National Heart, Lung, and Blood Institute in collaboration with the AIDS Clinical Trials Group and support from the National Institutes of Allergy and Infectious Diseases.
Ipsen today announced that the scientific journal Pediatrics published the detailed results of the phase III randomized study showing both the efficacy and the safety of Dysport in the treatment of dynamic equinus foot deformity, a condition associated with cerebral palsy in children.
Adolescent girls participating in high-impact physical activity, specifically basketball, running and gymnastics/cheerleading, appear to be at increased risk for developing stress fractures, according to a report posted online today that will appear in the August print issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.
The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
› Verified 7 days ago
Dr. Shervin Shahriari, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 355 New Shackle Island Road, Hendersonville, TN 37075 Phone: 615-338-1862 | |
Tadron Wilson, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 351 New Shackle Island Rd, Hendersonville, TN 37075 Phone: 615-824-0552 Fax: 615-824-9771 | |
Dr. Martin Olejcek, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 355 New Shackle Island Rd, Hendersonville, TN 37075 Phone: 615-338-1000 Fax: 615-338-1101 |